Another step from laboratory to market. Will cost RBM $15K/quarter and options for 100,000 shares of stock:
"Response Biomedical Engages The Trout Group
Wednesday February 11, 9:00 am ET
"Leading New York-based Investor Relations Firm to Facilitate Exposure to US Capital Markets
VANCOUVER, Feb. 11 /CNW/ - Response Biomedical Corp. (RBM: TSX Venture Exchange), today announced that it has engaged The Trout Group LLC, a leading New York based investor relations firm, to facilitate the Company's exposure to US capital markets by developing relationships with portfolio managers, investment bankers, industry analysts and the business news media. With extensive institutional investor relationships in the United States, Canada and Europe, The Trout Group provides strategic advisory and investor relations services to life science companies.
"As we continue to generate increasing revenue from commercial sales of multiple RAMP product lines including biodefense applications and the environmental detection of West Nile virus, the Company is well positioned for long term success," said Bill Radvak, President and CEO of Response Biomedical.
"As we move toward securing a US-listing, this is a strategically appropriate time to begin raising public awareness and corporate profile," added Radvak. "Having recently filed a Form 20-F Registration Statement with the US Securities and Exchange Commission, we believe The Trout Group will be instrumental in increasing the Company's support and following on Wall Street and other important financial centers."
"With the rebound in the capital markets, investors are eagerly searching out promising micro-cap companies that have not yet been discovered by Wall Street," said Jonathan Fassberg, President of The Trout Group. "With several products on the market and an emerging revenue stream, we are confident Response has the business fundamentals and the foundation for rapid growth to garner significant US investor attention."
"Pursuant to the engagement, Response Biomedical will provide compensation to The Trout Group of US$15,000 per quarter. In addition, The Trout Group will receive an option to purchase 100,000 common shares of Response Biomedical at an exercise price of $0.50, vesting quarterly and exercisable for a term of 2 years." |
